No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
12 Health Care Stocks Moving In Tuesday's After-Market Session
LIXTE Launches New Study to Determine If Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
Express News | Lixte Biotechnology Provides Update on Progress With Proprietary Compound, Lb-100, to Treat Ovarian and Colorectal Cancer
LIXTE Biotechnology Provides Update On Progress With Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
10-K: FY2024 Annual Report
Express News | Lixte Biotechnology Holdings Inc - Terminates Sales Agreement With Wallachbeth Capital